Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow Reinvestment Rate
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow Reinvestment Rate of 0.21x as of September 2025, reinvesting ₩1.42 Billion (capex ₩1.39 Billion plus investments ₩35.01 Million) from operating cash flow of ₩6.82 Billion. See 061250 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hwail Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hwail Pharmaceutical Co.Ltd across 10 annual periods. For the full cash flow conversion analysis, see 061250 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year capital reinvestment analysis for Hwail Pharmaceutical Co.Ltd. See 061250 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.24x | ₩84.20 Billion | ₩11.63 Billion | ₩34.63 Billion | ▲ +132.8% |
| 2023 | 3.11x | ₩21.84 Billion | ₩7.02 Billion | ₩2.10 Billion | ▲ +59.1% |
| 2021 | 1.95x | ₩39.26 Billion | ₩20.09 Billion | ₩2.47 Billion | ▲ +564.1% |
| 2019 | 0.29x | ₩1.09 Billion | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩1.55 Billion | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩513.62 Million | ₩8.34 Billion | ₩513.62 Million | ▼ -91.9% |
| 2016 | 0.76x | ₩7.29 Billion | ₩9.58 Billion | ₩413.00 Million | ▼ -52.4% |
| 2013 | 1.60x | ₩11.16 Billion | ₩6.97 Billion | ₩9.18 Billion | ▼ -79.2% |
| 2012 | 7.69x | ₩7.72 Billion | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩5.32 Billion | ₩7.86 Billion | ₩5.32 Billion | — |